Zavegepant用于偏头痛急性治疗的临床评估。

Clinical evaluation of zavegepant for the acute treatment of migraine.

作者信息

Fan Huiqiao, Wadolowski Janette, Shan Ryan, Contrera Gianni J, Polomoff Christina M

机构信息

University of Connecticut School of Pharmacy, Storrs.

出版信息

J Manag Care Spec Pharm. 2025 Jun;31(6):598-602. doi: 10.18553/jmcp.2025.31.6.598.

DOI:10.18553/jmcp.2025.31.6.598

PMID:40443004

Abstract

Zavegepant is the first intranasal calcitonin gene-related peptide receptor antagonist approved for the acute treatment of migraine and offers a new nonoral option for patients. This article reports the findings of a comprehensive literature review to assess zavegepant's safety and effectiveness. Evidence synthesis involved reporting findings from clinical trials and evaluating comparative effectiveness. This review was prepared by the University of Connecticut School of Pharmacy Academy of Managed Care Pharmacy (AMCP) Student Chapter. The student author group won the AMCP National Pharmacy and Therapeutics competition for their zavegepant product review in March 2024.

摘要

扎维吉泮是首个获批用于偏头痛急性治疗的鼻内降钙素基因相关肽受体拮抗剂，为患者提供了一种新的非口服选择。本文报告了一项全面文献综述的结果，以评估扎维吉泮的安全性和有效性。证据综合包括报告临床试验结果和评估比较有效性。本综述由康涅狄格大学药学院管理式医疗药学学会（AMCP）学生分会编写。学生作者团队因其在2024年3月对扎维吉泮的产品综述而赢得了AMCP全国药学与治疗学竞赛。